Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
life sciences
national blog main
clinical trials
drugs
fda
onpattro
patisiran
rna interference
akcea therapeutics
aminolevulinic acid
givosiran
hereditary transthyretin amyloidosis
inotersen
national top stories
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
tafamidis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
andrew fire
craig mello
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john maraganore
nobel prize
paul matteis
san francisco blog main
san francisco top stories
stifel financial
vyndaqel
What
alnylam
4
×
drug
medicine
rnai
4
×
fda
interference
pharmaceuticals
rna
ok
second
seek
speedy
afternoon
ago
alnylam’s
approval
approved
approves
cells
cleared
data
ema
employ
europe
far
follows
gene
gets
harmful
history
hits
indicated
landmark
make
making
market
method
mute
nasdaq
new
Language
Current search:
alnylam
×
rnai
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug